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Abstract 
There are many therapies available for the
management of low-grade lymphoma. With fol-
licular lymphoma, for example, combination of
chemotherapy and rituximab (immuno-chemo  -
therapy) and consecutive maintenance therapy
for 2 years is the current standard of care. To
date, the most widely used regimen seems to be
rituximab  combined  with  cyclo  phosphamide,
doxorubicin,  vincristine,  and  prednisone  (R-
CHOP). Substitution of liposomal doxorubicin
in  place  of  conventional  doxorubicin  may
improve outcomes in this indication, although
evidence for its use in low-grade lymphoma is
not  as  relevant  as  in  aggressive  lymphoma.
Bendamustine, in combination with rituximab,
has shown very good efficacy and tolerability in
several lymphoma types, particularly follicular
lymphoma  and  other  low-grade  lymphomas.
Other  combinations,  such  as  those  including
bortezomib and lenalidomide, are under investi-
gation in low-grade lymphoma, and the duration
of  rituximab  maintenance  therapy  following
bendamustine−rituximab-containing induction
is being researched by the German Study Group
for Indolent Lymphoma (StiL). 
Treatment of low-grade lymphoma 
Low-grade lymphomas are chronic diseases,
and some patients may live for many years fol-
lowing initial diagnosis.1 Therefore, for many
patients it is currently regarded as appropriate
not to treat immediately at diagnosis, but rather
to  watch  and  wait.  Once  patients  do  require
treatment, there are many therapies available:
chemotherapeutic agents known to be effective
in  low-grade  lymphoma  include  alkylating
agents,  anthracycline-based  regimens,  purine
analogs, and bendamustine. In addition, there
is the established monoclonal antibody therapy
rituximab, and newer antibodies such as ofatu-
mumab.  Patients  may  also  undergo  stem-cell
transplantation – either autologous or allogene-
ic – with or without myeloablation preceding
allogeneic transplantation. Finally, there is cur-
rently a small amount of experience available
on the use of techniques such as DNA vaccina-
tion or antisense therapy. 
Questions  about  the  long-term  outcome  of
following an initial watchful waiting approach
have been raised by a recent study, which com-
pared this approach with immediate treatment
with rituximab in patients with stage II, III or IV
asymptomatic  follicular  lymphoma  (FL).2 The
estimated  median  time  to  initiation  of  new
therapy among patients in the watchful waiting
group was 33 months, whereas among those
receiving rituximab the median time was not
reached at 4 years (P<0.001). There were also
significant differences in progression-free sur-
vival  between  the  observation  and  rituximab
arms (P<0.001), although no difference in over-
all  survival.  These  data  indicate  that  initial
treatment  with  rituximab  significantly  delays
the  need  for  new  therapy.  This  may,  in  the
future,  change  the  management  approach  to
patients with newly-diagnosed FL. 
It is unclear whether some patients with low-
grade lymphoma can be treated with curative
intent, particularly as patients at stages I and II,
and some at stage III (for example, those with
up to five lymph nodes involved), can live for a
long time after diagnosis. Usually treatment is
undertaken  to  manage  disease-associated
symptoms, such as B symptoms, hematopoietic
insufficiency (e.g. anemia, leukopenia, and/or
thrombocytopenia), rapid tumor progression, or
bulky disease. Some patients develop phenome-
na such as autoimmune hemolytic anemia or
idiopathic thrombocytopenic purpura as a con-
sequence of their disease, and others may have
recurrent infections as a result of hypogamma-
globulinemia, all of which require treatment. 
Standard therapy for low-grade
lymphoma 
At this time, combined immuno-chemother-
apy with rituximab followed by rituximab main-
tenance therapy for 2 years is the standard of
care for patients with FL (note that the most
appropriate maintenance therapy for all other
low-grade lymphomas is currently under inves-
tigation).  What  is  less  clear  is  the  best
chemotherapy to combine with rituximab. Che  -
motherapy  combinations  comprising  cyclo  -
phosphamide,  doxorubicin,  vincristine,  and
prednisone [CHOP; or cyclophosphamide, vin-
cristine,  and  prednisone  (CVP)]  are  well
accepted by clinicians. In addition, chlorambu-
cil-based  chemo  therapies  such  as  mitox-
antrone, chlorambucil, and prednisone (MCP),
and some fludarabine-based therapies [e.g. flu-
darabine, cyclophosphamide, and mitoxantrone
(FCM)] are commonly used, and bendamustine
therapy has been investigated with promising
results in these patients. Maintenance therapy
with rituximab is also the standard of care in
patients  with  low-grade  lymphoma.  This  has
been known for some time to be the optimal
approach  for  patients  with  relapsed  disease,
and the recent results of the PRIMA study indi-
cate that this is also the most effective treat-
ment strategy for patients with FL after first-
line treatment with rituximab plus chemother-
apy.3
Liposomal doxorubicin in low-grade
lymphoma 
There are currently few data on the use of non-
pegylated liposomal doxorubicin (NPLD) specifi-
cally in low-grade lymphoma. Some of the publi-
cations available are case series, studies involv-
ing only small numbers of patients, or studies of
patient populations with aggressive as well as
low-grade lymphomas. One retrospective study of
37 patients with lymphomas who were either eld-
erly or had cardiac comorbidities included three
with FL, two with chronic lymphocytic leukemia,
and one with multiple myeloma.4 These patients
received  NPLD  in  combination  chemotherapy,
and experienced a high rate of remission for this
poor-risk population [complete remission rates
were 75% for diffuse large B-cell lymphoma and
55%  for  T/NK-cell  neoplasm;  overall  response
rates (ORR) of 80% and 89%, respectively], with
no major cardiac toxicities. Rates of hematologic
toxicity were comparable to those for regimens
containing  conventional  anthracyclines.4
Similarly, in a prospective study of 35 elderly and
frail patients, five patients with FL received R-
COMP (R-CHOP with NPLD substituted for con-
ventional doxorubicin) as a first-line therapy: R-
COMP was effective and well tolerated, and no
cardiac events have been observed.5 Again, the
hematotoxicity of this combination was the same
as that seen with the R-CHOP regimen. 
A small study has also been conducted using a
combination  of  the  new  proteasome  inhibitor
bortezomib with NPLD, fludarabine, and ritux-
imab in 16 patients with refractory/relapsed man-
tle-cell lymphoma (MCL).6There was a good ORR
of 74% and 9 of 15 patients experienced a com-
plete response (CR) or unconfirmed CR. Rates of
neutropenia  (37.5%)  and  thrombocytopenia
(31.2%) were high, as expected; the rate of car-
diotoxicity was 12.5% (although no information
is  provided  on  how  this  was  defined).  The
authors therefore concluded that this combina-
tion therapy was effective and well tolerated. 
Hematology Reports 2011; volume 3(s3):e5
Correspondence: Dr Alexander Burchardt,
Department  of  Hematology,  Justus-Liebig  Uni  -
versity Hospital, Klinikstrasse 33, 35385 Giessen,
Germany.
Tel. +49.641.985.42651 - Fax: +49.641.985.42659.
E-mail:  Alexander.Burchardt@innere.med.uni-
giessen.de
Key words: low-grade lymphoma, treatment, rit-
uximab,  non-pegylated  liposomal  doxorubicin,
bendamustine.
Conflict of interest: the author reports no con-
flicts of interest. 
This work is licensed under a Creative Commons
Attribution NonCommercial 3.0 License (CC BY-
NC 3.0).
©Copyright A. Burchardt, 2011
Licensee PAGEPress, Italy
Hematology Reports 2011; 3(s3):e5
doi:10.4081/hr.2011.s3.e5[Hematology Reports 2011; 3(s3):e5] [page 15]
Bendamustine in low-grade 
lymphoma 
The  German  Study  Group  for  Indolent
Lymphoma (StiL) conducted a prospective, ran-
domized Phase III trial (NHL 1-2003) to compare
the efficacy of bendamustine plus rituximab (BR)
with  the  widely  accepted  R-CHOP  regimen  in
patients with low-grade lymphomas. The results
were presented at the 2009 American Society of
Hematology  meeting  as  an  oral  presentation.7
Bendamustine (90 mg/m2) was administered on
days 1 and 2, with rituximab on day 1, every 4
weeks for a maximum of six cycles. R-CHOP was
given every 3 weeks, for a maximum of six cycles.
In total, 513 patients were evaluable for efficacy
and toxicity, most of whom (54%) had FL, with the
remainder having MCL (18%), marginal zone lym-
phoma (MZL; 13%), Waldenström macroglobuline-
mia (WM; 8%), and small lymphocytic leukemia
(SLL;  4%).  Most  patients  had  stage  IV  disease
(77%) with bone marrow infiltration. 
There was a clear difference between BR and R-
CHOP in the incidence of grade III and IV hemato-
toxicities. There were significantly fewer cycles of
BR,  compared  with  R-CHOP,  in  which  patients
experienced grade III or IV leucocytopenia (12.1%
versus 38.2%,  respectively),  neutropenia  (10.7%
versus 46.5%),  or  required  granulocyte  colony-
stimulating factor (4.0 versus20.0; P<0.0001 in all
cases). BR was associated only with grade 1 alope-
cia and there was a low incidence of paraesthesias
and  stomatitis  compared  with  R-CHOP.  On  the
other hand, BR was associated with more skin
reactions  (erythema)  than  R-CHOP.  Almost  all
patients in the BR treatment arm received the full
dose of chemotherapy (96.1% of cycles), whereas a
smaller proportion of cycles of R-CHOP were com-
pleted at the full dose of chemotherapy (88.8%). 
The ORR was good in both groups: 93.8% for BR
and 93.5% for R-CHOP.7 The CR rate was signifi-
cantly higher with BR versus R-CHOP (40.1% ver-
sus 30.8%;  P=0.0323).  Progression-free  survival
(PFS) was significantly longer with BR (median
PFS 54.8 months) compared with R-CHOP (medi-
an 34.8 months) at a median observation period of
32 months [hazard ratio (HR) 0.5765; 95% confi-
dence  interval  (CI)  0.4292-0.7783;  P=0.0002].
Similarly, event-free survival was 54 months for BR
and 31 months for R-CHOP (HR 0.6014; 95% CI
0.4515-0.7845;  P=0.0002).  Another  key  measure
was the time to next treatment, which had not
been reached in the BR arm versus a median of
40.7 months with R-CHOP (HR 0.5416; 95% CI
0.3897-0.7491; P=0.0002). In summary, this study
demonstrated that BR significantly improved PFS
and CR rates, compared with R-CHOP, in patients
with FL, MCL, and WM. BR was also associated
with a better tolerability profile than R-CHOP.
Research into new treatments and
strategies for low-grade lymphoma
The StiL study is now underway to investi-
gate the effect of duration of maintenance ther-
apy with rituximab in FL, and the effect of ritux-
imab maintenance therapy in other low-grade
lymphoma entities. In the NHL 7-2008 (MAIN-
TAIN) study (NCT00877214), patients with FL
will be randomized to either 2 or 4 years of rit-
uximab maintenance therapy, every 2 months,
following BR induction therapy. The main effi-
cacy outcome will be PFS. In addition, infec-
tious complications can be studied prospective-
ly in this patient population, which is important
because  it  has  been  reported  that  rituximab
treatment is associated with neutropenia and
increases  infectious  complications.8 Another
part  of  the  MAINTAIN  study  is  designed  to
investigate the efficacy of maintenance therapy
in other forms of low-grade lymphoma. Patients
with WM, MZL, or MCL will be randomized to
either 2 years of maintenance therapy with rit-
uximab every 2 months, or 2 years of watch and
wait,both following BR induction. Again, effica-
cy will be measured using PFS. 
Studies with other agents are also ongoing.
As discussed above, combination therapy with
bortezomib, NPLD, fludarabine, and rituximab
was shown in a small study to be effective in
relapsed  MCL.6 The  StiL  NHL  8-2010  study
plans to further investigate the efficacy of com-
bination therapy with bortezomib in patients
with relapsed low-grade lymphomas. Lenalido  -
mide is another promising therapy in low-grade
lymphomas,  which  has  demonstrated  good
results  in  patients  with  several  lymphoma
types,  in  hard-to-treat  relapsed  or  refractory 
disease.9,10
Conclusions
Low-grade lymphomas will become chronic
diseases, and many patients will require treat-
ment over long periods of time, with many treat-
ment cycles. R-CHOP is commonly used to treat
low-grade lymphoma, though chlorambucil- and
fludarabine-based regimens are also used. The
efficacy  and  toxicity  of  R-CHOP  may  be
improved by substitution of NPLD into this com-
bination, although data on the use of liposomal
doxorubicin  are  currently  more  focused  on
aggressive  lymphomas.  BR  therapy  has  pro-
duced promising results in several types of low-
grade lymphoma, both in terms of efficacy and
safety outcomes, and is recommended in the
National  Comprehensive  Cancer  Network
(NCCN)  Clinical  Practice  Guidelines  in
Oncology  (V  1.2011)  as  first-line  therapy  for
indolent  lymphoma.11 The  use  of  rituximab
maintenance treatment after BR induction is
currently under investigation in different lym-
phoma types. In addition, the efficacy of a com-
bination treatment of bortezomib and BR will be
studied. The use of lenalidomide also warrants
further investigation in low-grade lymphoma. 
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